Results 61 to 70 of about 15,255 (159)

A Meta-Analysis of Platinum Plus Gemcitabine or Vinorelbine for Advanced Non-small Cell Lung Cancer

open access: yesChinese Journal of Lung Cancer, 2009
Background and objective Platinum plus the third-generation agent doublet chemotherapy is the standard regimens and first line chemotherapy for advanced non-small cell lung cancer (NSCLC).
Guanghui GAO   +5 more
doaj  

Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer

open access: yesInternational Journal of Nanomedicine, 2021
Shuhang Wang,1 Jingxin Gou,2 Yue Wang,1 Xinyi Tan,2 Linxuan Zhao,1 Xiangqun Jin,1 Xing Tang2 1Department of Pharmaceutics, College of Pharmacy Sciences, Jilin University, Changchun, 130021, Jilin, People’s Republic of China; 2Department of ...
Wang S   +6 more
doaj  

Dynamic Evaluation of Vinorelbine-Induced Phlebitis of Dorsalis Pedis Vein in a Rat Model

open access: yesShiyan dongwu yu bijiao yixue
ObjectiveTo dynamically observe the clinical symptoms and pathological changes in a rat model of vinorelbine-induced phlebitis via injection into the dorsalis pedis vein.MethodsTwenty-eight 11-week-old male SPF-grade SD rats were randomly divided into a ...
JIANG Meng   +7 more
doaj   +1 more source

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study

open access: yesBMC Cancer, 2008
Background The vinka-alkaloyd vinorelbine is a potentially valuable treatment in patients with HER2-positive, trastuzumab-resistant advanced breast cancer.
Viale Giuseppe   +8 more
doaj   +1 more source

Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies

open access: yesOncology Reviews, 2011
Metastatic breast cancer (BC) remains an incurable disease and clinical benefit and prolongation of time to progression are the main end-points in advanced setting. A safe and feasible schedule of administration is the principal option in pre-treated and
Fausto Petrelli, Sandro Barni
doaj   +1 more source

Overcoming Breast Cancer Drug Resistance: A Novel Approach Using siRNA-Mediated P-glycoprotein Downregulation to Enhance Vinorelbine Efficacy [PDF]

open access: yesAdvanced Pharmaceutical Bulletin
Purpose: Cancer, the second leading cause of mortality worldwide, represents a global health challenge, primarily due to drug resistance. Vinorelbine is a chemotherapeutic agent that disrupts cancer cell growth by targeting microtubules and inducing ...
Zahra Abbasfard   +5 more
doaj   +1 more source

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

open access: yesBMC Cancer, 2010
Background The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve ...
Müller Volkmar   +9 more
doaj   +1 more source

Response Rate,Side Effect and Reduction in Tumor Size of Vinorelbine, Gemcitabine and Taxanes as First Line Setting of Advanced Squamous Cell Carcinoma of the Lung

open access: yesDiyala Journal of Medicine
Background: Squamous-cell carcinoma (SCC) of the lung is a kind of non-small-cell lung carcinoma. Cytotoxic chemotherapy has been found to deliver benefits to patients in advanced disease settings. Objective: To compare response rate and side effects
Shahbaa Ahmed AL Qadasi,   +1 more
doaj   +1 more source

David Slays Goliath: Exceptional Efficacy of Oral Vinorelbine in Conquering Metastatic Finger Angiosarcoma

open access: yesJournal of Cancer Research and Practice
Angiosarcoma (AS) is a rare and aggressive disease originating from blood or lymphatic vessel endothelium, representing
Te-Lin Hsu, San-Chi Chen
doaj   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Home - About - Disclaimer - Privacy